Episode 13: You get blinatumomab! You get blinatumomab!
WolverHeme Happy Hour
00:00
The Challenge of Speculating on Random Subgroups
As of right now, I'd say adult patients getting a BFM backbone with minimal asparagenase therapy, BLIN improves their survival. The problem in the United States is who is using the E-COG-2993 backbone currently? Right. But then we have to mention there's only 100 sub patients in each arm, which makes it really hard to break down what we need to.
Transcript
Play full episode
